Q1 Earnings Estimate for RVMD Issued By HC Wainwright

Revolution Medicines, Inc. (NASDAQ:RVMD) – HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Revolution Medicines in a report issued on Thursday, August 27th. HC Wainwright analyst R. Burns anticipates that the company will post earnings per share of ($2.06) for the quarter. HC Wainwright has a “Buy” rating and a $280.00 price objective on the stock. The consensus estimate for Revolution Medicines’ current full-year earnings is ($8.82) per share. HC Wainwright also issued estimates for Revolution Medicines’ Q2 2027 earnings at ($1.70) EPS, Q3 2027 earnings at ($1.62) EPS, Q4 2027 earnings at ($1.47) EPS and FY2027 earnings at ($6.86) EPS.

Revolution Medicines (NASDAQ:RVMD) last issued its earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter last year, the company earned ($1.31) earnings per share.

Several other analysts also recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Revolution Medicines in a report on Friday, July 17th. Raymond James Financial reiterated a “strong-buy” rating and set a $248.00 target price on shares of Revolution Medicines in a report on Thursday. Sanford C. Bernstein raised their target price on shares of Revolution Medicines from $151.00 to $179.00 and gave the company a “market perform” rating in a research report on Friday, August 21st. Truist Financial boosted their price target on shares of Revolution Medicines from $231.00 to $239.00 and gave the company a “buy” rating in a report on Thursday. Finally, TD Cowen upgraded shares of Revolution Medicines to a “strong-buy” rating in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $193.28.

Revolution Medicines Price Performance

RVMD opened at $221.15 on Friday. Revolution Medicines has a 12-month low of $37.56 and a 12-month high of $224.31. The company has a current ratio of 11.38, a quick ratio of 11.38 and a debt-to-equity ratio of 0.40. The business’s fifty day simple moving average is $192.43 and its 200-day simple moving average is $148.17. The company has a market capitalization of $47.40 billion, a price-to-earnings ratio of -25.07 and a beta of 1.39.

Insider Transactions at Revolution Medicines

In related news, insider Mark A. Goldsmith sold 80,000 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $209.20, for a total transaction of $16,736,000.00. Following the sale, the insider owned 267,330 shares of the company’s stock, valued at $55,925,436. This trade represents a 23.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Margaret A. Horn sold 60,400 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $160.17, for a total value of $9,674,268.00. Following the sale, the chief operating officer directly owned 158,222 shares in the company, valued at approximately $25,342,417.74. The trade was a 27.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 212,497 shares of company stock worth $38,206,486. Company insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Revolution Medicines

A number of large investors have recently added to or reduced their stakes in RVMD. California State Teachers Retirement System lifted its position in shares of Revolution Medicines by 26,920.9% during the second quarter. California State Teachers Retirement System now owns 44,659,351 shares of the company’s stock valued at $8,363,803,000 after buying an additional 44,494,074 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Revolution Medicines by 6.7% in the 4th quarter. Vanguard Group Inc. now owns 16,719,886 shares of the company’s stock worth $1,331,739,000 after buying an additional 1,056,792 shares during the last quarter. Janus Henderson Group PLC grew its position in shares of Revolution Medicines by 8.3% in the 4th quarter. Janus Henderson Group PLC now owns 12,303,502 shares of the company’s stock worth $980,036,000 after buying an additional 947,448 shares during the last quarter. Nextech Invest Ltd. raised its stake in shares of Revolution Medicines by 20.7% during the 4th quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock worth $332,472,000 after acquiring an additional 1,304,347 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP raised its stake in shares of Revolution Medicines by 6.8% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 6,644,403 shares of the company’s stock worth $529,227,000 after acquiring an additional 421,112 shares in the last quarter. 94.34% of the stock is currently owned by institutional investors.

More Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: FDA approval creates a major commercial catalyst. RASONQUE is described as the first broad RAS-targeted medicine approved for metastatic pancreatic cancer, potentially establishing a new treatment option for patients with limited alternatives. FDA approval announcement
• Positive Sentiment: Analysts remain bullish after the approval. HC Wainwright reiterated a “Buy” rating and a $280 price target, above the referenced $221.15 price, while forecasting a narrower FY2027 loss of $6.86 per share. Truist also raised its target to $239 and Wedbush increased its target to $225, both maintaining positive ratings.
• Positive Sentiment: Early launch expectations are favorable. RBC reportedly views the RASONQUE launch as capable of moving quickly, while Oppenheimer said the product’s label expands Revolution Medicines’ commercial opportunity. The company’s decision to remain independent could allow shareholders to retain greater value from the drug’s potential.
• Neutral Sentiment: Near-term financial results will still reflect a development-stage business. HC Wainwright projects quarterly 2027 losses of $2.06, $1.70, $1.62 and $1.47 per share, for a full-year loss of $6.86 per share. Investors are likely to focus on prescription trends, reimbursement and initial revenue after the launch.
• Negative Sentiment: RASONQUE’s $39,800 monthly price may create access and reimbursement risks. Although the price supports substantial revenue potential, it could attract scrutiny from payers and policymakers or slow patient access, tempering some of the enthusiasm surrounding the FDA decision. RASONQUE pricing article

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.